IBJNews

Roche Diagnostics to get indirect boon from new test

Back to TopCommentsE-mailPrintBookmark and Share

Last week's U.S. approval of a new Roche drug-diagnostic combo for skin cancer won't by itself produce much revenue for its diagnostic division, but it could indirectly be a boon for the company's U.S. diagnostic headquarters in Indianapolis.

The U.S. Food and Drug Administration approved a new genetic test to go along with a new Roche melanoma drug on Aug. 17. The BRAF V600 Mutation Test for use in Roche’s cobas 4800 fluid analyzers will determine which patients are eligible for treatment with Zelboraf, the new medicine for patients with late-stage, metastatic melanoma, the most dangerous type of skin cancer.

The approval of the drug and test together is a first in U.S. history, although many pharmaceutical and diagnostic firms are working to achieve the same feat.

“That really to me substantiates what Roche has been saying for several years, that personalized health care is ... critical for the future,” Jack Phillips, CEO of Roche Diagnostics’ U.S. operations, said in an interview.

The money in this approval will come from the drug, which will sell for about $113,000 for a year’s treatment, according to an Aug. 17 report by Goldman Sachs Group Inc. Goldman analysts project Zelboraf could reach sales of $535 million by 2015, with other analysts saying it eventually could approach $1 billion per year.

Nearly 70,000 Americans are diagnosed with metastatic melanoma each year. But the number of patients that are in late stages of the disease and have the BRAF V600 mutation likely will only be about 7,000 per year, Deutsche Bank analyst Tim Race wrote in an Aug. 17 report.

Roche Diagnostics will sell the BRAF test for about $120 to $150 for each time it’s run, Phillips said. So if Deutsche Bank’s estimates are correct, the test would generate about $1 million a year in revenue.

But the real value to Roche Diagnostics is if it helps sell more cobas 4800 machines to laboratories, which will then run all of Roche’s other tests. The cobas 4800 runs a variety of DNA-based tests, such as ones for Chlamydia and gonorrhea, as well as for the human papillomavirus, or HPV.

“It really hits medical value and hits a home run around medical value,” Phillips said. He added, “That creates big demand for one test, but it will also drive customers to bring in Roche’s platform to run all our other tests.”

Not to mention that each cobas 4800 system costs between $250,000 and $300,000.

The new combination was developed in California, where Roche Diagnostics’ molecular research and development team is and where Roche subsidiary Genentech Inc. developed the drug. Roche's corporate headquarters is in Basel, Switzerland.

But sales of the test and the cobas 4800 will be handled out of the Indianapolis office.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. to mention the rest of Molly's experience- she served as Communications Director for the Indianapolis Department of Public Works and also did communications for the state. She's incredibly qualified for this role and has a real love for Indianapolis and Indiana. Best of luck to her!

  2. Shall we not demand the same scrutiny for law schools, med schools, heaven forbid, business schools, etc.? How many law school grads are servers? How many business start ups fail and how many business grads get low paying jobs because there are so few high paying positions available? Why does our legislature continue to demean public schools and give taxpayer dollars to charters and private schools, ($171 million last year), rather than investing in our community schools? We are on a course of disaster regarding our public school attitudes unless we change our thinking in a short time.

  3. I agree with the other reader's comment about the chunky tomato soup. I found myself wanting a breadstick to dip into it. It tasted more like a marinara sauce; I couldn't eat it as a soup. In general, I liked the place... but doubt that I'll frequent it once the novelty wears off.

  4. The Indiana toll road used to have some of the cleanest bathrooms you could find on the road. After the lease they went downhill quickly. While not the grossest you'll see, they hover a bit below average. Am not sure if this is indicative of the entire deal or merely a portion of it. But the goals of anyone taking over the lease will always be at odds. The fewer repairs they make, the more money they earn since they have a virtual monopoly on travel from Cleveland to Chicago. So they only comply to satisfy the rules. It's hard to hand public works over to private enterprise. The incentives are misaligned. In true competition, you'd have multiple roads, each build by different companies motivated to make theirs more attractive. Working to attract customers is very different than working to maximize profit on people who have no choice but to choose your road. Of course, we all know two roads would be even more ridiculous.

  5. The State is in a perfect position. The consortium overpaid for leasing the toll road. Good for the State. The money they paid is being used across the State to upgrade roads and bridges and employ people at at time most of the country is scrambling to fund basic repairs. Good for the State. Indiana taxpayers are no longer subsidizing the toll roads to the tune of millions a year as we had for the last 20 years because the legislature did not have the guts to raise tolls. Good for the State. If the consortium fails, they either find another operator, acceptable to the State, to buy them out or the road gets turned back over to the State and we keep the Billions. Good for the State. Pat Bauer is no longer the Majority or Minority Leader of the House. Good for the State. Anyway you look at this, the State received billions of dollars for an assett the taxpayers were subsidizing, the State does not have to pay to maintain the road for 70 years. I am having trouble seeing the downside.

ADVERTISEMENT